跳至主要内容
临床试验/NCT01261533
NCT01261533Unknown1 期

The Multi-center Exploratory Clinical Trials for the Evaluation of Flexibility, Efficacy, and Safety of a Foldable Capsular Vitreous Body in the Treatment of Severe Retinal Detachment

GuangZhou WeiShiBo Biotechnology Co., ltd9 个研究点 分布在 1 个国家目标入组 122 人开始时间: 2010年9月1日最近更新:
适应症
干预措施

试验速览

阶段
1 期
发起方
入组人数
122
试验地点
9
主要终点
Complete retinal reattach rate at the 52 weeks after implantation of the FCVB

研究概览

简要总结

The purpose of this study is to determine the feasibility, primary safety and efficacy of foldable capsular vitreous body (FCVB) in the treatment of retinal detachment, based on the multi-center clinical trial.

详细描述

Previous clinical trial have demonstrated that foldable artificial vitreous body (FCVB),with balanced salt solution (BSS) filled in 11 patients during three-months observation,or silicone oil filled in 4 patients during a six-month observation respectively, can be transplanted into the vitreous body easily, and performances good safety and efficacy in the treatment of severe retinal detachment.

Current multi-center clinical trial was to determine the feasibility, primary safety and efficacy of FCVB with silicone oil filled in the treatment of retinal detachment in 120 patients.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •age range from 18 to 65, Refractive error less than ±3D
  • •Corrected visual acuity less than 0.05
  • •ocular axial length is 16 to 25mm
  • •severe retinal detachment that can not be treated by current artificial vitreous body:
  • •Severe unilateral ocular perforating injuries, compounded retinal or choroidal detachments resulted from retinal rupture or retinal choroidal hemorrhage.
  • •Severe unilateral ocular rupture injuries result in retina or choroid defect.
  • •Giant posterior scleral rupture injuries that can not be repaired.
  • •Silicone oil can't be taken out for a long time with incomplete reattachment.
  • •Participants have undergone retinal detachment surgery and silicone oil tamponade twice or more, however, retina is re-detachment after silicone oil removal.
  • •Participants can understand the aim of this clinical trial and sign the informed consent form

排除标准

  • •Participants have a silica gel allergy or scar diathesis
  • •entophthalmia
  • •The contralateral eye suffered from intraocular surgery
  • •uncontrollable the other eye diseases
  • •Corrected visual acuity of contralateral eye less than 0.4
  • •Proliferative diabetic retinopathy
  • •the lens of target eye is transparent
  • •Serious heart, lung, liver and kidney dysfunction
  • •pregnancy, preparation for pregnancy during clinical trial and breast-feeding female
  • •drug abuse or alcoholism
  • •participated the other drug or medical devices clinical trial before screening of this trial
  • •Any research doctors consider that the condition of participants will hinder the clinical trial--Prone to mental stress, loss control of mood, depression etc.
  • •Patient adherence is so poor that study procedures can not be finished

研究组 & 干预措施

FCVB team

Experimental

the vitreous cavity is tamponaded with the foldable capsular vitreous body (FCVB)

干预措施: foldable capsular vitreous body(FCVB) (Device)

结局指标

主要结局

Complete retinal reattach rate at the 52 weeks after implantation of the FCVB

时间窗: 52 weeks after implantation of the FCVB

次要结局

  • Retinal reattach rate, Visual function,and Silicone oil change(Before surgery, 3days,1 week, 2 weeks, 4 weeks, 8 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks after FCVB implantation surgery (If patients ask for the delay of removal of FCVB, the patients must received a review every three months))

研究者

发起方
GuangZhou WeiShiBo Biotechnology Co., ltd
申办方类型
Industry
责任方
Sponsor

研究点 (9)

Loading locations...

相似试验